Reminyl retard

PreclinicalSmall molecule

UUniversity Hospital, Bonn

Reminyl retard is one of 36 small molecule programs targeting Alzheimer's Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's DiseaseUnknown status

Alzheimer's DiseasePreclinical

Unknown status

Competition

Competitive Landscape

54 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

6 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Namenda

AbbVie

Phase 2

2 6

Briviact

UCB

Phase 2

1 7

Leukine

Sanofi

Phase 2

1 8

Niacor

AbbVie

Phase 2

1 9

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 10

Hytrin

AAbbott

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Unknown status·UUniversity Hospital, Bonn·N/A·NCT00637442·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Reminyl retard. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Reminyl retard compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Reminyl retard. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bonn company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Bonn

Reminyl retard

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News